Sometimes, a breakthrough matters not only because of what it does for patients today, but because of what it makes possible for tomorrow.
|Articles|April 1, 2005
- Volume 0 0
ACE Inhibitors Lower Pneumonia Threat
Advertisement
Patients who have had a stroke can ward off the risk of pneumonia withangiotensin-converting enzyme (ACE) inhibitors. For the study, theresearchers evaluated the risk of pneumonia in >1000 patients who had hada stroke. The patients involved in the 35-month study were given 1 of 3 treatments:ACE inhibitors, other blood pressure drugs, or a placebo. The datashowed 2.8% of the ACE inhibitor group developed pneumonia, comparedwith 8.5% of the patients in the other 2 groups. (The findings were reportedin Neurology, February 9, 2005.)
Articles in this issue
over 21 years ago
Internet Prescribing 2005over 21 years ago
COMPOUNDING HOTLINEover 21 years ago
Breakfast Cereals Take a Step in the Right Directionover 21 years ago
Refined Carbs Cause Obesityover 21 years ago
Obesity Problematic for Young Transplant Patientsover 21 years ago
High BMI Linked to Dementiaover 21 years ago
When Does Compounding Become Manufacturing?over 21 years ago
Talking to Your Diabetes Patients About Fiberover 21 years ago
Counseling Guide for Avoiding Asthma Triggersover 21 years ago
RA Drug Does Not Alter Cholesterol RatioNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
SubscribeAdvertisement
Related to this article
Pharmacogenomic-guided prescribing uses genetic data to protect patients from dangerous toxicities and get them the right drug at the right dose from the start.
As accessible health care providers, pharmacists can raise awareness about the proper use of OTC blood glucose meters and continuous glucose monitoring devices.
Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.
As earning years peak, so do spending and responsibility—here’s where midcareer pharmacists should focus their financial decision-making.
Despite the controversy surrounding mRNA's role in the COVID-19 response, the technology's broader promise—to prevent, treat, and even cure a host of diseases—is coming into focus.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring
2
What Different Communities Taught Me About Patient Care
3
Patients Report Early, Sustained Functional Gains With First-Line Zongertinib in HER2-Mutant NSCLC
4
FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia
5